glp-1 drug market size Receptor Agonist Size, Share GLP-1 Receptor Agonist Market Size

In recent years, higher doses of some GLP-1 RAs have been used for obesity treatment, with liraglutide (3 mg) and semaglutide (2.4 mg) showing marked efficacy in inducing WL

Sure enough, exendin-4 displayed all the same effects as GLP-1, triggering insulin secretion from the pancreas and slowing digestion

Dulaglutide and lixisenatide continue to be key molecules in terms of importance for the time being, however, as the pipeline molecules can offer a wide variety of innovative formulations the competition is growing

As evidence accumulates on the broader benefits of GLP-1 therapies, pressure is building to expand reimbursement for obesity indications